Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Canadian Natural Resources Ltd. (CNQ) vs BIO-TECHNE Corp (TECH) Price & Performance

Canadian Natural Resources Ltd.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Canadian Natural Resources Ltd. vs BIO-TECHNE Corp — how do they compare? Canadian Natural Resources Ltd. trades at $42.69 (market cap $88.15B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.10B). The key difference: Canadian Natural Resources Ltd. is far larger — about 7.9× BIO-TECHNE Corp's market cap, and Canadian Natural Resources Ltd. pays the higher dividend (4.13%). Which is the better fit depends on your goals.

CNQTECH
Market Cap
$88.15B$11.10B
Sector
EnergyHealth
52-Week High
$50.55$71.38
52-Week Low
$29.31$43.31
Enterprise Value
$99.38B$11.18B
Dividend Yield
4.13%0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Canadian Natural Resources Ltd.

CNQ trades at $43.05, up 2.97% today, with a bullish technical signal supported by moving averages and ADX. The stock shows strong fundamentals with a P/E of 11.8, net income margin of 24.5%, and consistent earnings beats in recent quarters. Recent news highlights its robust asset base and operational efficiency amid volatile oil markets. Cash flow remains positive, with 2025 net cash flow at $542 million.

Outlook is positive with analyst consensus strongly favoring Buy (75%), driven by valuation appeal and shareholder returns via dividends and buybacks. Key risks include oil price volatility and rising debt-to-asset ratio, which increased to 22.04% in 2024. The stock's proximity to its 52-week high suggests cautious optimism, but fundamentals support long-term growth potential.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.

The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Canadian Natural Resources Ltd.

Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.

Read more on CNQ

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH